Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS-R): A randomized, placebo-controlled trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 3, 2017, Pages 387-393

  Neal, Bruce ^a,b,c,d   Perkovic, Vlado ^a,b   Matthews, David R ^e   Mahaffey, Kenneth W ^f   Fulcher, Greg ^b   Meininger, Gary ^g   Erondu, Ngozi ^g   Desai, Mehul ^g   Shaw, Wayne ^g   Vercruysse, Frank ^h   Yee, Jacqueline ^g   Deng, Hsiaowei ^g   de Zeeuw, Dick ⁱ  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

cardiovascular disease; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

ALBUMIN; ANTICOAGULANT AGENT; CANAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PLACEBO; RENIN INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGE; ALBUMINURIA; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART DEATH; HEART FAILURE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METHODOLOGY; MICROALBUMINURIA; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RISK REDUCTION; SAMPLE SIZE; SEX RATIO; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; DOUBLE BLIND PROCEDURE; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; ALBUMINURIA; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85013890365     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12829     Document Type: Article

References (25)

1. United States Renal Data Systems. USRDS annual data report: epidemiology of kidney disease in the United States. 2015. http://www.usrds.org/2015/view/Default.aspx. Accessed October 6, 2016.
2. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-878.
3. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
5. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192.
6. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
7. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-840.
8. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
9. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.
10. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411-419.
11. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)–a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223.
12. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262-274.
13. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853-862.
14. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680-1686.
15. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independent of glycemic effects. J Am Soc Nephrol. 2017;28(1):368–375.
16. US Food and Drug Administration. FDA Briefing Document. NDA 204042. Invokana (canagliflozin) Tablets. Applicant: Janssen Pharmaceuticals, Inc. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. January 10, 2013. 2013.
17. Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302(1):R75-R83.
18. Lambers Heerspink HJ, Gansevoort RT. Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin J Am Soc Nephrol. 2015;10(6):1079-1088.
19. Makino H, Haneda M, Babazono T, et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: angiotensin II blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) study. Hypertens Res. 2008;31(4):657-664.
20. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941-1951.
21. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907-917.
22. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372(9647):1394-1402.
23. European Medicines Agency (EMA). SGLT2 inhibitors (previously Canagliflozin) Article-20 procedure – Amended review started. 2016. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors_(previously_Canagliflozin)/human_referral_prac_000059.jsp&mid=WC0b01ac05805c516f. Accessed October 6, 2016.
24. US Food and Drug Administration. Invokana and Invokamet (canagliflozin): drug safety communication—new information on bone fracture risk and decreased bone mineral density. 2015. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm461876.htm. Accessed November 11, 2015.
25. ® (dapagliflozin) tablets, for oral use [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2015.